TET2 mutations occur in around 50% of chronic myelomonocytic leukemia (CMML), a subtype of myelodysplastic syndrome/myeloid proliferative neoplasm (MDS/MPN) [124], as well as in around 30% of myeloproliferative neoplasms and AML [125]. This evidence concerns the gene TET2 and myeloproliferative disorder.